A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC)

被引：0
|
作者：
Pili, R.
Haggman, M.
Stadler, W. M.
Gingrich, J. R.
Assikis, V. J.
Bjork, A.
Forsberg, G.
Carducci, M. A.
Armstrong, A. J.
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[2] Uppsala Univ, Uppsala, Sweden
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Peachtree Hematol Oncol, Atlanta, GA USA
[6] Act Biotech, Lund, Sweden
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4510
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects
    Mehta, Amit R.
    Armstrong, Andrew J.
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (01) : 9 - 18
  • [32] Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Groshen, Susan G.
    Quinn, David I.
    Goldkorn, Amir
    Martel, Cynthia L.
    Pinski, Jacek K.
    Kuhn, Pater
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Radiopharmaceutical and Chemotherapy Combinations in Metastatic Castrate-Resistant Prostate Cancer: A New Beginning?
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2417 - 2418
  • [34] A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
    William R. Schelman
    Glenn Liu
    George Wilding
    Thomas Morris
    De Phung
    Robert Dreicer
    Investigational New Drugs, 2011, 29 : 118 - 125
  • [35] A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
    Schelman, William R.
    Liu, Glenn
    Wilding, George
    Morris, Thomas
    Phung, De
    Dreicer, Robert
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (01) : 118 - 125
  • [36] A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC).
    Ryan, Charles J.
    Rosenthal, Mark
    Ng, Siobhan
    Alumkal, Joshi J.
    Picus, Joel
    Gravis, Gwenaelle
    Fizazi, Karim
    Forget, Frederic
    Machiels, Jean-Pascal H.
    Zhu, Min
    Jiang, Joe
    Dubey, Sarita
    Loh, Elwyn
    Gerritsen, Winald R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [37] Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC)
    Aragon-Ching, J. B.
    Jain, L.
    Draper, D.
    Gulley, J. L.
    Arlen, P. M.
    Wright, J. J.
    Jones, E.
    Chen, C. C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Treatment sequencing in metastatic castrate-resistant prostate cancer
    Sartor, Oliver
    Gillessen, Silke
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 426 - 431
  • [39] Abiraterone for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
    Beckett, Robert D.
    Rodeffer, Kathryn M.
    Snodgrass, Rachel
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1016 - 1024
  • [40] Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer
    Francini, Edoardo
    Fiaschi, Anna Ida
    Petrioli, Roberto
    Francini, Filippo
    Bianco, Vincenzo
    Perrella, Armando
    Paganini, Giovanni
    Laera, Letizia
    Roviello, Giandomenico
    ANTI-CANCER DRUGS, 2014, 25 (04) : 472 - 477
12345